These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

174 related items for PubMed ID: 11876141

  • 1. [Leflunomide--a new disease modifying anti-rheumatic agent].
    Rødevand E, Kvien TK, Johnsen V.
    Tidsskr Nor Laegeforen; 2001 Nov 10; 121(27):3181-4. PubMed ID: 11876141
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of leflunomide in active rheumatoid arthritis.
    Smolen JS, Emery P.
    Rheumatology (Oxford); 2000 Jun 10; 39 Suppl 1():48-56. PubMed ID: 11001380
    [Abstract] [Full Text] [Related]

  • 3. Safety evaluation of leflunomide in rheumatoid arthritis.
    Keen HI, Conaghan PG, Tett SE.
    Expert Opin Drug Saf; 2013 Jul 10; 12(4):581-8. PubMed ID: 23668332
    [Abstract] [Full Text] [Related]

  • 4. Leflunomide in the treatment of rheumatoid arthritis.
    Li EK, Tam LS, Tomlinson B.
    Clin Ther; 2004 Apr 10; 26(4):447-59. PubMed ID: 15189743
    [Abstract] [Full Text] [Related]

  • 5. [Leflunomide--the first specific disease-modifying drug against rheumatoid arthritis].
    Ringertz B, Petersson I.
    Lakartidningen; 2001 Feb 07; 98(6):566-7. PubMed ID: 11475244
    [Abstract] [Full Text] [Related]

  • 6. Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group.
    Cohen S, Cannon GW, Schiff M, Weaver A, Fox R, Olsen N, Furst D, Sharp J, Moreland L, Caldwell J, Kaine J, Strand V.
    Arthritis Rheum; 2001 Sep 07; 44(9):1984-92. PubMed ID: 11592358
    [Abstract] [Full Text] [Related]

  • 7. Update 2011: leflunomide in rheumatoid arthritis - strengths and weaknesses.
    Behrens F, Koehm M, Burkhardt H.
    Curr Opin Rheumatol; 2011 May 07; 23(3):282-7. PubMed ID: 21427581
    [Abstract] [Full Text] [Related]

  • 8. Benefit-risk assessment of leflunomide: an appraisal of leflunomide in rheumatoid arthritis 10 years after licensing.
    Alcorn N, Saunders S, Madhok R.
    Drug Saf; 2009 May 07; 32(12):1123-34. PubMed ID: 19916579
    [Abstract] [Full Text] [Related]

  • 9. The efficacy of leflunomide monotherapy in rheumatoid arthritis: towards the goals of disease modifying antirheumatic drug therapy.
    Smolen JS, Emery P, Kalden JR, Van Riel PL, Dougados M, Strand CV, Breedveld FC.
    J Rheumatol Suppl; 2004 Jun 07; 71():13-20. PubMed ID: 15170903
    [Abstract] [Full Text] [Related]

  • 10. [Leflunomide for active rheumatoid arthritis].
    Andresen PN, Hansen G, Hørslev-Petersen K.
    Ugeskr Laeger; 2000 Sep 25; 162(39):5228-32. PubMed ID: 11043056
    [Abstract] [Full Text] [Related]

  • 11. Leflunomide for rheumatoid arthritis.
    Drug Ther Bull; 2000 Jul 25; 38(7):52-4. PubMed ID: 11027115
    [Abstract] [Full Text] [Related]

  • 12. Leflunomide and rheumatoid arthritis: new preparation. Neither the safest nor the most effective slow-acting antirheumatic drug.
    Prescrire Int; 2001 Apr 25; 10(52):36-9. PubMed ID: 11718154
    [Abstract] [Full Text] [Related]

  • 13. Methotrexate versus leflunomide in rheumatoid arthritis: what is new in 2011?
    Singer O, Gibofsky A.
    Curr Opin Rheumatol; 2011 May 25; 23(3):288-92. PubMed ID: 21378570
    [Abstract] [Full Text] [Related]

  • 14. Leflunomide Aventis Pharma.
    Kaplan MJ.
    Curr Opin Investig Drugs; 2001 Feb 25; 2(2):222-30. PubMed ID: 11816835
    [Abstract] [Full Text] [Related]

  • 15. Toward a definition and method of assessment of treatment failure and treatment effectiveness: the case of leflunomide versus methotrexate.
    Wolfe F, Michaud K, Stephenson B, Doyle J.
    J Rheumatol; 2003 Aug 25; 30(8):1725-32. PubMed ID: 12913927
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group.
    Smolen JS, Kalden JR, Scott DL, Rozman B, Kvien TK, Larsen A, Loew-Friedrich I, Oed C, Rosenburg R.
    Lancet; 1999 Jan 23; 353(9149):259-66. PubMed ID: 9929017
    [Abstract] [Full Text] [Related]

  • 17. Leflunomide, a novel immunomodulator for the treatment of active rheumatoid arthritis.
    Goldenberg MM.
    Clin Ther; 1999 Nov 23; 21(11):1837-52; discussion 1821. PubMed ID: 10890256
    [Abstract] [Full Text] [Related]

  • 18. Lefunomide in combination therapy.
    Kalden JR, Smolen JS, Emery P, van Riel PL, Dougados M, Strand CV, Breedveld FC.
    J Rheumatol Suppl; 2004 Jun 23; 71():25-30. PubMed ID: 15170905
    [Abstract] [Full Text] [Related]

  • 19. Safety and retention of combination triple disease-modifying anti-rheumatic drugs in new-onset rheumatoid arthritis.
    Cummins L, Katikireddi VS, Shankaranarayana S, Su KY, Duggan E, Videm V, Pahau H, Thomas R.
    Intern Med J; 2015 Dec 23; 45(12):1266-73. PubMed ID: 26384029
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.